July 21, 2021 -- Aldevron made a deal to supply plasmid DNA that will enable AavantiBio to advance its gene therapies for rare genetic diseases.
Aldevron will supply plasmids to AavantiBio's planned vector core and contract development manufacturing organization partners. Also, the partnership includes materials for proof-of-concept and good lab practices (GLP) toxicology studies for future programs.